The Zhitong Finance App learned that Kangchen Pharmaceutical (01681) rose more than 6%. As of press release, it had risen 6.43% to HK$6.95, with a turnover of HK$10.196 million.

According to the news, Conson Pharmaceutical announced yesterday that the company will hold a board meeting on May 24, 2024 (that is, next Friday) to review and approve the issuance of a special dividend (special dividend) and handle any other business (if any). If approved by the board, the company will publish a separate announcement after the board meeting to set out details of the special dividend.

Kangchen Pharmaceutical achieved operating income of 2.59 billion yuan (unit, same below) in 2023, an increase of 10.7% over the previous year; net profit to mother was 785 million yuan, an increase of 14.9% over the previous year. Among them, the sales revenue of nephrology drugs was 1.74 billion yuan, up about 11% year on year; sales revenue of the leading product, uretoxin granules, was about 1.65 billion yuan, up about 10.2% year on year.